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ABSTRACT
Objective: The introduction of biosimilar medicines in markets can bring savings to health systems, expanding the population’s access to various 
treatments. This study aims to analyze the price competition of biological agents and their biosimilars in Brazil within the scope of rheumatoid 
arthritis.
Methods: Prices for 14 presentations of original and biosimilar medicines were analyzed from January 2003 to October 2019 in Brazil. Prices were 
taken from official lists and were noted since launch and during the later trading period. Prices were converted to United States dollars and adjusted 
for inflation for the 2003 base year.
Results: In Brazil, during this review period, prices of biopharmaceuticals decreased in real values, reaching up to a 50% reduction. The introduction 
of biosimilars did not affect the price sharing of biological medicines.
Conclusion: Biosimilar antirheumatics do not yet have a significant impact on the price of biologics marketed in Brazil. A change in this scenario is 
expected in the medium and long term.
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INTRODUCTION
Biopharmaceutical or biological agents are complex molecules 
of high molecular mass obtained from tissues of animal origin or 
biotechnological procedures carried out under controlled conditions. 
The intended biological activity depends on strictly controlled 
modifications made to the molecules [1-3].
Biosimilars are biological products equivalent in quality, 
effectiveness, and safety to an original biological medicine called the 
reference product [4,5]. Their goal is to increase access to biological 
therapy, reducing costs [1,6]. It should be noted that there are high 
risks of research and development as well as high costs in their 
production [7].
The introduction of biological drugs in the treatment of rheumatic 
diseases such as rheumatoid arthritis (RA) has changed the lives of 
many patients in the past 20 years [8,9]. They are a new generation 
of drugs that are effective and expensive. While actively slowing the 
progression of disease symptoms, they can represent an important 
economic burden for individuals and health systems [3,4].
European health systems finance biosimilars with average prices up 
to 30% lower than reference products [4]. Daily treatment prices have 
also decreased, driven by a greater degree of competition. In the United 
States (US), legal and patent issues prevent biosimilars from entering 
the market faster [10], although their prices are lower than those of the 
original medicines [11].
In Latin America, the increase in the use of this class of drugs should 
boost competition, benefiting governments, prescribers, and users 
of the health system, with both lower prices and greater access to 
treatments [12]. For this block, there is a concentration of regulatory 
studies, but few price analyses [7,13-15]. In Colombia, although there 
is some information about price, there is little systematization and 
there is no classification or details about this drug class [7]. In Brazil, 
although biological products represent 22% of the total market 
turnover, they sold only 3.8% of pharmaceutical presentations in 2017. 
The absorption of these products took place mainly between 2016 and 
2017, with the federal government responsible for more than 50% of 
purchases seeking to expand and ensure the population’s access to 
these inputs [3].
As little is known about the price evolution of these products and 
considering that RA is a disease that employs biological agents in 
patients who do not respond to first-line therapy, the objective of this 
study is to analyze the effects of price competition between agents and 
their biosimilars in Brazil in the scope of RA.
METHODS
The records and prices of antirheumatics of biological origin and their 
biosimilars were analyzed. The registration information was taken 
from the page of the National Health Surveillance Agency (Anvisa) [16]. 
The Clinical Protocol and Therapeutic Guidelines for the treatment of 
RA were reviewed, looking for other therapeutic possibilities that had 
not been captured to complement the registration data [17].
A sample of 14 antirheumatic biological agents was defined for the 
treatment of RA, 10 original products and 4 biosimilars, from the list 
of launches between 2003 and 2019. These products were listed by the 
year of manufacture, pharmaceutical form(s), and packaging. The unit 
of analysis of the study was the product, in equal concentrations and 
packaging. Any drug association was excluded from the study.
The year of publication of the authorization to market the biosimilar 
guided the monitoring of price developments in the following 
periods. The prices of the first biosimilar and of its respective original 
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biopharmaceutical were taken at the following times: In its first 
commercialization; and 1, 2, and 3 years after launch when possible. 
Some drugs had their prices monitored for 4 years and others for 
1 or 2 years, or only their initial prices were compared. The price of 
the packaging with the largest quantity or cheapest presentation was 
taken.
Reference wholesale prices were used as the basis for the survey, 
referring to the Anvisa page, in the price lists of the Medicines Market 
Regulation Chamber (CMED), starting in 2003 [18]. The standard 
established was the maximum consumer price (price monitoring cell), 
referring to 18% of the tax on the circulation of goods and provision of 
services.
Real prices were estimated, starting in the base year of 2003, using 
the Wholesale Price Index – Global Supply (IPA-OG) – Industrial 
products [19]. All prices were standardized/converted into US dollars, 
using the exchange rates of the Central Bank of Brazil [20], year by year.
This study did not require approval from the institutional review board 
or informed consent, as it is based on public data and does not involve 
patient records.
RESULTS
The evolution of prices between 2003 and 2019 in dollars and in reais 
in nominal values and in 2003 is shown in Fig. 1.
The prices of original biological medicines have changed in real terms, 
mainly in the last decade. Most of these prices fell by approximately 20%. 
Adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, 
and tocilizumab had their prices reduced by 12.0%, 20.8%, 18.8%, 
20.8%, 15.0%, and 19.0%, respectively. Exceptions were abatacept, 
with a decrease of 38.9%; rituximab, with a decrease of 49.6%; and 
tofacitinib, with a decrease of 2.3%, partly due to its presence in the 
market since 2015.
The drugs sold before 2008 were those that had the largest drop: 
adalimumab – 27.4%; etanercept – 53.6%; and rituximab – 55.0%. 
However, with similar price decreases, the last two had different 
trajectories. The reduction in the price of etanercept was 43% until 
2008, while the price of rituximab fell only 15% in the same period. In 
2009, the paths are reversed, with the first decreasing by approximately 
10% and the second decreasing by 57%.
The appearance of golimumab and certolizumab pegol as of 2012 
created at least four price levels: Three for biologicals and one for 
biosimilars. One of these price levels, at 2003 prices, up to a thousand 
reais, includes certolizumab pegol, abatacept, tocilizumab, and 
rituximab. Another price level, up to approximately two thousand 
reais, includes etanercept, golimumab, and tocilizumab. Tofacitinib 
and adalimumab remain at a higher level, with values above three 
thousand reais. The last group includes biosimilars. The average prices 
for these groups are R$ 895.00, R$ 2,100.00, R$ 3,700.00, and R$ 
1,500.00 (Fig. 2).
The influence of biosimilars on the prices of original drugs is not clear. In 
addition to the short time of commercialization, from 2016 onward, the 
downward trend in the values practiced by biologicals has not changed. 
Even though their prices are lower than their direct substitutes, they 
have higher levels than the product group of up to a thousand reais.
Fig. 1: Prices of biological and biosimilar medicines for rheumatoid arthritis in Brazil, in reais and dollars, from 2003 to 2019. Source: 
Own elaboration, based on the prices of the CMED [17]
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DISCUSSION
In Brazil, there were 10 approved biological medicines in the analyzed 
period, which were divided into three price groups. Four below one 
thousand reais, four at the level of two thousand reais and two above 
three thousand reais. The biosimilars were distributed in a segment 
with values of approximately fifteen hundred reais. It was decided to 
use the reference prices for retail indicated by the federal government, 
even though we were aware of possible disparities between the 
fixed values and those paid by the public administration in bidding 
processes [21]. On the one hand, Brazil has a complex and costly tax 
model for medicines; on the other hand, despite the information on 
how public resources are used, having gained more transparency in 
recent years, they need even more transparency so that we understand 
how they are used as an instrument of social control [22].
The short authorization period for the commercialization of biosimilar 
agents for RA in Brazil, of almost 2 years for etanercept, four for 
infliximab and approximately 1 year for rituximab, does not allow an 
in-depth analysis. Despite this, there seems to be no evidence, at least in 
the short term, that there will be a reduction in the price of the original 
biologicals due to biosimilars. This is because, for the group of drugs 
below a thousand reais, there will be no impact. For the group based on 
two thousand reais, there should also be no competitive price, since the 
relationship with biosimilars is already within the expected reduction 
margin.
Adalimumab and tofacitinib, which have prices above three thousand 
reais, would remain. However, it does not seem feasible to expect a 
significant drop. The two drugs already face competition from other 
biologicals, with lower prices, without their market values having 
decreased. Analogous to the insertion of generics that increased the 
offer of products with lower prices without decreasing the reference 
prices [23], the biosimilars seem to be moving in the same direction.
Therapies based on biological products have had a significant impact 
on several diseases in which medical needs are not satisfactorily met. 
In contrast, the high cost of treatment with these drugs constitutes an 
effective barrier to access in several parts of the world, including in 
more developed countries [24].
Brazil seems to behave in contrast to the international scenario, where 
the impact of the entry of biosimilars has been observed. In Spain, 
biosimilars are priced 30% less than the original biopharmaceuticals, 
as agreed upon by Decree [8,25]. German social insurance receives 
discounts of 10% for medicines with the same manufacturing process. 
In Italy, prices initially fell between 15 and 22%, and today, this decrease 
has been progressive to encourage access to biosimilars [8].
Nevertheless, it is hoped that these products, as well as generic drugs, 
can reduce the cost of medical intervention in various regions of 
the world as patents for biologicals expire [26,27]. However, unlike 
generics, which were introduced at prices up to 40% lower than the 
originals, reaching over time up to 68% [23], some authors expect that 
the price reductions of biosimilars will not be greater than 30% [28,29].
CONCLUSION
The main objective of this study was to analyze the extent of the price 
difference between the biological agents used in the treatment of RA in 
Brazil and its biosimilars, discussing the possible effects of competition 
between them. Biological medicines showed the highest growth rate, 
37.5% between 2015 and 2017, accounting for 22% of total sales in the 
last year. In contrast, biosimilars were in the drug class with the lowest 
number of units sold (168.1 million reais) [3,30].
The prices of all original organic products have been decreasing 
steadily in real values since 2003. This drop was greater than 50% for 
some of them. The structure of the Brazilian market was designed in the 
form of three groups of price levels. It would be important to observe 
carefully, as more drugs are introduced in the market, the configuration 
of the competitive process, seeking to foresee behaviors and trends, as 
it happens in Europe.
In the past 4 years, biosimilar medicines obtained their registration 
with Anvisa and started to be commercialized, but their impact is still 
unknown. Although the period is short for definitive evaluation, this 
market seems to follow what has happened in generics. Increased 
supply of products with less expensive prices has a low effect on the 
price level practiced for reference products. The optimism, both in 
international and Brazilian literature, that biosimilars may cause a 
Fig. 2 : Distribution of medicines by price group. Source: Own elaboration
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decrease in the values of innovative biologicals seems to have no basis 
for support, at least in the short term.
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